TABLE 1.
Summary of the clinical trials in HFpEF patients reporting the treatment outcomes of some pharmacological therapy options.
| Acronym | Identifier | Participants | Intervention | Outcomes | References |
|---|---|---|---|---|---|
| PARAGON HF | NCT01920711 | 4,822 | Sacubitril-valsartan | Potential benefit in women and those patients with midrange LV ejection fraction | Solomon et al. (2018) |
| RELAX | NCT00763867 | 216 | Sildenafil | The study did not observe a significant improvement | Redfield et al. (2013) |
| SOCRATES PRESERVED | NCT01951638 | 477 | Vericiguat | Failed to improve NT-proBNP blood levels, although the quality of life improved | Pieske et al. (2017) |
| CAPACITY-HFpEF | NCT03254485 | 196 | Praliciguat | No effect in peak VO2 or echocardiographic parameters | Udelson et al. (2020) |
| VITALIY HFpEF | NCT03547583 | 789 | Vericiguat | Did not improve the physical limitation score of the Kansas City Cardiomyopathy Questionnaire (KCCQ) | Armstrong et al. (2020) |
| DILATE-1 | NCT01172756 | 36 | Riociguat | Improved exploratory hemodynamic and echocardiographic parameters. No effect on mean pulmonary artery pressure (mPAP) | Bonderman et al. (2014) |
| D-HART 2 | NCT02173548 | 31 | Anakinra | Reduced CRP and NT-proBNP plasma levels. Failed to improve aerobic exercise capacity or ventilation efficiency | Van Tassell et al. (2018) |
| TOPCAT | NCT00094302 | 1767 | Spironolactone | Reduction in all-cause mortality associated with spironolactone therapy in women | Merrill et al. (2019) |
| EMPEROR-preserved | NCT03057951 | 5,899 | Empagliflozin | Reduced the combined risk of cardiovascular death or hospitalization regardless of the presence or absence of diabetes | Anker et al. (2021) |